Zopiclone discontinuation: review of 25 studies assessing withdrawal and rebound phenomena.
Bianchi
M
M
Théraplix Groupe Rhône-Poulenc, Paris, France.
Musch
B
B
D053961:Azabicyclo Compounds; D004305:Dose-Response Relationship, Drug; D004569:Electroencephalography / Q000187:drug effects; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects; D008297:Male; D010879:Piperazines / Q000009:adverse effects*; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced*; D012894:Sleep Stages / Q000187:drug effects; D013375:Substance Withdrawal Syndrome / Q000209:etiology*
D053961:Azabicyclo Compounds; D006993:Hypnotics and Sedatives; D010879:Piperazines; C515050:zopiclone